<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638712</url>
  </required_header>
  <id_info>
    <org_study_id>2020-006</org_study_id>
    <secondary_id>2020-A01266-33</secondary_id>
    <nct_id>NCT04638712</nct_id>
  </id_info>
  <brief_title>Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients</brief_title>
  <acronym>PROTECT-03</acronym>
  <official_title>Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de cancérologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UR 3072 - Mitochondries, Stress oxydant, Protection musculaire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de cancérologie Strasbourg Europe</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, prospective and monocentric study. This study includes the&#xD;
      evaluation before and after (neo)adjuvant therapy of :&#xD;
&#xD;
        -  one group of patients receiving anthracyclines and taxanes&#xD;
&#xD;
        -  a second group of patients receiving anthracyclines, taxanes and trastuzumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Actual">May 20, 2021</completion_date>
  <primary_completion_date type="Actual">May 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vastus lateralis cross-sectional area</measure>
    <time_frame>Between Week 18 and 24 after chemotherapy</time_frame>
    <description>Measured from muscle microbiopsy sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alteration of patients body composition</measure>
    <time_frame>Baseline (=before chemotherapy) and Between Week 18 and 24 (=after chemotherapy)</time_frame>
    <description>Assessment using bio-impedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alteration of patients strength</measure>
    <time_frame>Baseline (=before chemotherapy) and Between Week 18 and 24 (=after chemotherapy)</time_frame>
    <description>Assessment of maximal isometric muscle strength for knee extensors measured with force sensors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alteration of patients muscle architecture</measure>
    <time_frame>Baseline (=before chemotherapy) and Between Week 18 and 24 (=after chemotherapy)</time_frame>
    <description>Assessment using muscle ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alteration of patients quality of life</measure>
    <time_frame>Baseline (=before chemotherapy) and Between Week 18 and 24 (=after chemotherapy)</time_frame>
    <description>Self-assessment questionnaire Functional Assessment of Cancer Therapy - General (FACT-G) (version 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patient cachexia</measure>
    <time_frame>Baseline (=before chemotherapy) and Between Week 18 and 24 (=after chemotherapy)</time_frame>
    <description>Questionnaire Functional Assessment of Anorexia/Cachexia Therapy (FAACT) (version 4)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1 without trastuzumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 with trastuzumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microbiopsy sample</intervention_name>
    <description>before and after chemotherapy</description>
    <arm_group_label>Group 1 without trastuzumab</arm_group_label>
    <arm_group_label>Group 2 with trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level</intervention_name>
    <description>before and after chemotherapy</description>
    <arm_group_label>Group 1 without trastuzumab</arm_group_label>
    <arm_group_label>Group 2 with trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For group 1 without trastuzumab :&#xD;
&#xD;
          -  Patients must be ≥ 18 years old&#xD;
&#xD;
          -  Patients with breast cancer stage I to III&#xD;
&#xD;
          -  Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, without&#xD;
             trastuzumab&#xD;
&#xD;
          -  Patients must have a social security coverage&#xD;
&#xD;
          -  Patients able to speak, read and understand French&#xD;
&#xD;
        For group 2 with trastuzumab :&#xD;
&#xD;
          -  Patients must be ≥ 18 years old&#xD;
&#xD;
          -  Patients with breast cancer grade I to III&#xD;
&#xD;
          -  Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, with&#xD;
             trastuzumab&#xD;
&#xD;
          -  Patients must have a social security coverage&#xD;
&#xD;
          -  Patients able to speak, read and understand French&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  Previous chemotherapy&#xD;
&#xD;
          -  Patients with known chronic pathology (musculoskeletal disorders, autoimmune, vascular&#xD;
             or neuromuscular disease)&#xD;
&#xD;
          -  Pacemaker implantation&#xD;
&#xD;
          -  Contraindication to physical condition evaluation&#xD;
&#xD;
          -  Contraindication to local anesthesia required for microbiopsy&#xD;
&#xD;
          -  Patients &lt; 18 years old or patients ≥ 18 years old under guardianship, or supervision&#xD;
&#xD;
          -  Psychiatric, musculoskeletal or neurologic disorders&#xD;
&#xD;
          -  Women that are pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut de Cancerologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

